Hepatitis C and renal transplantation: A review on historical aspects and current issues

Reviews in Medical Virology

Volumn 18, Issue 6, 2008, Pages 375-386

  Hosseini Moghaddam, Seyed Mohammadmehdi ^a   Alavian, Seyed Moayed ^b   Kermani, Nahid Arjmand ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Baqiyatallah Research Center for Gastroenterology and Liver Disease   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; CYCLOSPORIN A; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANTIVIRAL THERAPY; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEMODIALYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; KIDNEY TRANSPLANTATION; LIVER BIOPSY; MONOTHERAPY; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; PROGNOSIS;

EID: 57049099701     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.590     Document Type: Review

References (160)

1. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38(5): 919-934.
2. Pol S, Debure A, Degott C, et al. Chronic hepatitis in kidney allograft recipients. Lancet 1990; 335(8694): 878-880.
3. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51(4): 981-999.
4. Zucker K, Cirocco R, Roth D, et al. Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation 1994; 57(6): 832-840.
5. Roth D, Fernandez JA, Babischkin S, et al. Transmission of hepatitis C virus with solid organ transplantation: incidence and clinical significance. Transplantation Proc 1993; 25(1 Pt 2): 1476-1477.
6. Tesi RJ, Waller K, Morgan CJ, et al. Transmission of hepatitis C by kidney transplantation - the risks. Transplantation 1994; 57(6): 826-831.
7. Vincenti F, Lake J, Wright T, Kuo G, Weber P, Stempel C. Nontransmission of hepatitis C from cadaver kidney donors to transplant recipients. Transplantation 1993; 55(3): 674-675.
8. Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights. Nephrol Dial Transplant 2000; 15(suppl 8): 74-76.
9. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52(3): 843-861.
10. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36(1): 3-10.
11. Hwang EA, Kang MJ, Han SY, Park SB, Kim HC. Viral infection following kidney transplantation: long-term follow-up in a single center. Transplantation Proc 2004; 36(7): 2118-2119.
12. Huang CC, Liaw YF, Lai MK, Chu SH, Chuang CK, Huang JY. The clinical outcome of hepatitis C virus antibody-positive renal allograft recipients. Transplantation 1992; 53(4): 763-765.
13. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65(5): 667-670.
14. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Transplantation Proc 1998; 30(7): 3270-3272.
15. Durlik M, Gaciong Z, Rowinska D, et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998; 11(suppl 1): S135-S139.
16. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78(5): 745-750.
17. Melon S, Galarraga MC, Villar M, et al. Hepatitis C virus reactivation in anti-hepatitic C virus-positive renal transplant recipients. Transplantation Proc 2005; 37(5): 2083-2085.
18. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol 2007; 2: 563-575.
19. Kliem V, van den Hoff U, Brunkhorst R, et al. The long-term course of hepatitis C after kidney transplantation. Transplantation 1996; 62(10): 1417-1421.
20. Manga Sahin G, Sahin S, Kantarci G, Ergin H. Impact of hepatitis C virus infection on patient and graft survival in kidney transplantation. Transplantation Proc 2006; 38(2): 499-501.
21. Fabrizi F, Lunghi G, Marai P, et al. Virological and histological features of hepatitis C virus (HCV) infection in kidney transplant recipients. Nephrol Dial Transplant 1996; 11(1): 159-164.
22. Ebrahim Pour S, Hashemi SN, Kooshavar H, Argani H. Study of hepatitis C in hemodialysis and kidney transplant patients in Tabriz, 1995-96. Medical Journal of Tabriz University of Medical Sciences & Health Services 1999; 44(33): 3-8.
23. Einollahi B, Hajarizadeh B, Bakhtiari S, et al. Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living renal allograft recipients. J Gastroenterol Hepatol 2003; 18(7): 836-840.
24. Rostaing L, Izopet J, Cisterne JM, et al. Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: correlation with clinicopathological features. Transplantation 1998; 65(7): 930-936.
25. Roth D, Zucker K, Cirocco R, et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61(6): 886-889.
26. Perez RM, Ferraz ML, Figueiredo MS, et al. Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients. J Med Virol 2003; 69(4): 489-494.
27. Natov SN, Lau JYN, Ruthazer S, et al. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. Kidney Int 1999; 56: 700-706.
28. Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol 2004; 74(2): 246-252.
29. Hosseini-Moghaddam SM, Keyvani H, Kasiri H, et al. Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran - a multi-center study. J Med Virol 2006; 78(5): 569-573.
30. Pedroso S, Martins L, Fonseca L et al. Impact of hepatitis C virus on renal transplantation: association with poor survival. Transplantation Proc 2006; 38(6): 1890-1894.
31. Ponz E, Campistol JM, Bruguera M, et al. Hepatitis C virus infection among kidney transplant recipients. Kidney Int 1991; 40(4): 748-751.
32. Stempel CA, Lake J, Kuo G, Vincenti F. Hepatitis C - its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 1993; 55(2): 273-276.
33. Roth D. Hepatitis C virus infection and the renal allograft recipient. Nephron 1995; 71(3): 249-253.
34. Berthoux F. Hepatitis C virus infection and disease in renal transplantation. Nephron 1995; 71(4): 386-394.
35. Pereira BJ. Hepatitis C in transplantation. Nephrol Dial Transplant 1996; 11(8): 1520-1522.
36. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42(4): 631-657.
37. Behzad-Behbahani A, Mojiri A, Tabei SZ, et al. Outcome of hepatitis B and C virus infection on graft function after renal transplantation. Transplantation Proc 2005; 37(7): 3045-3047.
38. Poordad FF, Fabrizi F, Martin P. Hepatitis C infection associated with renal disease and chronic renal failure. Semin Liver Dis 2004; 24(suppl 2): 69-77.
39. Klauser R, Franz M, Traindl O, et al. Hepatitis C antibody in renal transplant patients. Transplantation Proc 1992; 24(1): 286-288.
40. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29(1): 257-263.
41. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66(4): 471-476.
42. Chan TM, Lok AS, Cheng IK. Hepatitis C in renal transplant recipients. Transplantation 1991; 52(5): 810-813.
43. Rostaing L, Izopet J, Cisterne JM, et al. Prevalence of antibodies to hepatitis C virus and correlation with liver disease in renal transplant patients. Am J Nephrol 1997; 17(1): 46-52.
44. Fabrizi F, Marai P, Erba G, et al. Hepatitis C virus infection in kidney graft recipients: a study with second-generation assays. Nephrol Dial Transplant 1992; 7(11): 1164-1165.
45. Lau JY, Davis GL, Brunson ME, et al. Hepatitis C virus infection in kidney transplant recipients. Hepatology 1993; 18(5): 1027-1031.
46. Roth D, Zucker K, Cirocco R, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45(1): 238-244.
47. Mahmoud IM, Sobh MA, Amer GM, et al. A prospective study of hepatitis C viremia in renal allograft recipients. Am J Nephrol 1999; 19(5): 576-585.
48. Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis C virus infection in adult renal graft recipients. Transplantation Proc 2005; 37(2): 940-941.
49. Roth D, Fernandez JA, Babischkin S, et al. Detection of hepatitis C virus infection among cadaver organ donors: evidence for low transmission of disease. Ann Intern Med 1992; 117(6): 470-475.
50. Boletis JN, Iniotaki-Theodoraki A, Psichogiou M, et al. Immune status in renal transplant recipients with hepatitis C virus infection. Transplantation Proc 2002; 34(8): 3205-3208.
51. Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis 2004; 43(1): 131-139.
52. Gursoy M, Bilezikci B, Colak T, et al. Histologic outcome of hepatitis C virus infection in renal transplant recipients and the effect of pretransplantation interferon treatment. Transplantation Proc 2000; 32(3): 558-560.
53. Alric L, Di-Martino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123(5): 1494-1499.
54. Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005; 5(7): 1704-1712.
55. Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006; 82(7): 853-856.
56. Zylberberg H, Nalpas B, Carnot F, et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17(1): 129-133.
57. Rohr MS, Lesniewski RR, Rubin CA, et al. Risk of liver disease in HCV-seropositive kidney trans-plant recipients. Ann Surg 1993; 217(5): 512-516; discussion 6-7.
58. Savas N, Ocal S, Colak T, Karakayali H, Yilmaz U, Haberal M. Clinical course of hepatitis C virus infection in renal transplant recipients. Transplantation Proc 2007; 39(4): 984-986.
59. Kamar N, Sandres-Saune K, Selves J, et al. Longterm ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42(1): 184-192.
60. Perez RM, Ferreira AS, Silva IS, et al. Hepatitis C virus infection in renal transplant patients: a comparative study with immunocompetent patients. Clin Transplant 2005; 19(6): 763-768.
61. Perez RM, Ferreira AS, Medina-Pestana JO, et al. Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease? J Clin Gastroenterol 2006; 40(5): 444-448.
62. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation. hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60(8): 7199-805.
63. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11(7): 1343-1353.
64. Mas V, Alvarellos T, Chiurchiu C, Camps D, Massari P, de Boccardo G. Hepatitis C virus infection after renal transplantation: viral load and outcome. Transplantation Proc 2001; 33(1-2): 1791-1793.
65. Izopet J, Rostaing L, Sandres; K, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181(3): 852-858.
66. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46(6): 1700-1704.
67. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002-june 10-12, 2002. Hepatology 2002; 36(suppl 1): S3-S20.
68. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74(4): 427-437.
69. Munoz De Bustillo E, lbarrola C, Colina F, et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am Soc Nephrol 1998; 9: 1109-1113.
70. Toth CM, Pascual M, Chung RT, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66(9): 1254-1258.
71. Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106(4): 994-999.
72. Calanca LN, Fehr T, Jochum W, et al. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. J Clin Virol 2007; 39(1): 54-58.
73. Pouteil-Noble C, Tardy JC, Chossegros P, et al. Coinfection by hepatitis B virus and hepatitis C virus in renal transplantation: morbidity and mortality in 1098 patients. Nephrol Dial Transplant 1995; 10(suppl 6): 122-124.
74. Morales JM. Hepatitis C and renal transplantation: outcome of patients. Nephrol Dial Transplant 1995; 10(suppl 6): 125-128.
75. Morales JM, Prieto C, Colina F, Andres A, Moreno F, JL R. Does cyclosporin induce clinical remission of dialysis-acquired active chronic hepatitis? Nephron 1989; 51: 146-147.
76. Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325(7): 454-460.
77. Shu KH, Lan JL, Wu MJ, et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004; 77(12): 1894-1896.
78. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5(6): 1452-1461.
79. Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol 2004; 30(1): 110-114.
80. Narula AS, Hooda A, Anand AC, Patrikar S. Impact of hepatitis C virus infection in renal transplant recipients. Indian J Gastroenterol 2005; 24(4): 151-154.
81. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39(4): 1147-1171.
82. Fabrizi F, Martin P. Management of hepatitis B and C virus infection before and after renal transplantation. Current Opinion in Organ Transplantation 2006; 11: 583-588.
83. Ozgur O, Boyacioglu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10(11): 2104-2106.
84. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59(10): 1426-1431.
85. Harihara Y, Kurooka Y, Yanagisawa T, Kuzuhara K, Otsubo O, Kumada H. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplantation Proc 1994; 26(4): 2075.
86. Magnone M, Holley JL, Shapiro R, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59(7): 1068-1070.
87. Therret E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients: a pilot study. Transplantation 1994; 58(5): 625-628.
88. Unal E, Turkmen F, Sevinc C, Kiziler AR, Aydemir B, Titiz I. Outcome of renal allograft in Turkish patients with pretransplantation hepatitis C virus infection. Transplantation Proc 2006; 38(10): 3448-3450.
89. Fabrizi F, Martin P, Bunnapradist S. Treatment of chronic viral hepatitis in patients with renal disease. Gastroenterol Clin North Am 2004; 33(3): 655-670, xi.
90. Zucker K, Cirocco R, Roth D, et al. Prospective longitudinal assessment of hepatitis C virus infection after renal transplantation. Transplantation Proc 1995; 27(1): 943-944.
91. Baid S, Tolkoff-Rubin N, Saidman S, et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3(1): 74-78.
92. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74(3): 512-516.
93. Fabrizi F, Lunghi G, Dixit V, Martin P. Metaanalysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Alimentary Pharmacology & Therapeutics 2006; 24(10): 1413-1422.
94. Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20(6): 677-683.
95. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients: pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14(11): 2704-2709.
96. Diego JM, Roth D. Treatment of hepatitis C infection in patients with renal disease. Curr Opin Nephrol Hypertens 1998; 7(5): 557-562.
97. Hanafusa T, Ichikawa Y, Yazawa K, et al. Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy. Transplantation Proc 1998; 30(1): 122-124.
98. Hanafusa T, Ichikawa Y, Kyo M, et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. Transplantation Proc 1995; 27(1): 956-957.
99. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplantation Proc 1999; 31(7): 2887-2889.
100. Ozdemir BH, Ozdemir FN, Sezer S, Colak T, Haberal M. De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplantation Proc 2006; 38(2): 492-495.
101. Morales JM. Hepatitis C virus infection and renal disease after renal transplantation. Transplantation Proc 2004; 36(3): 760-762.
102. Cattral MS, Hemming AW, Wanless IR, et al. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 1999; 67(9): 1277-1280.
103. Karaca C, Besisik F, Akyuz F, Dincer D, Sever MS, Okten A. Ribavirin treatment in patients with chronic hepatitis C infection who had renal transplantation. Dig Surg 2005; 22(1-2): 113.
104. Garnier JL, Chevallier P, Dubernard JM, Trepo C, Touraine JL, Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplantation Proc 1997; 29(1-2): 783.
105. Fontaine H, Vallet-Pichard A, Equi-Andrade C, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78(6): 853-857.
106. Daoud S, Garnier JL, Chossegros P, Chevallier P, Dubernard JM, Touraine JL. Hepatitis C virus infection in renal transplantation. Transplantation Proc 1995; 27(2): 1735.
107. Kamar N, Izopet J, Alric L, Rostaing L. Lack of evidence for ribavirin monotherapy ef.cacy on liver fibrosis in hepatitis C virus positive renal transplant patients. Transplantation 2005; 79(12): 1770-1771; author reply 1.
108. Gane EJ, Tibbs CJ, Ramage JK, Portmann BC, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995; 8(1): 61-64.
109. Hu SL, Jaber BL. Ribavirin monotherapy for hepatitis C virus-associated membranous nephropathy. Clin Nephrol 2005; 63(1): 41-45.
110. Pham HP, Feray C, Samuel D, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998; 54(4): 1311-1319.
111. Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000; 69(5): 991-994.
112. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38(5): 1282-1288.
113. Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313(1): 42-47.
114. Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19(1): 111-122.
115. Ichikawa Y, Kishikawa H, Nishimura K, et al. Retrospective study of the effects of cyclosporine in comparison with azathioprine on renal transplant recipients infected with hepatitis C virus. Transplantation Proc 2006;38(10): 3451-3453.
116. Luciani G, Bossola M, Muscaritoli M, et al. Sustained response with negative serum HCVmRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C. J Nephrol 2003; 16(3): 417-420.
117. Kamar N, Boulestin A, Selves J, et al. Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J Med Virol 2005; 76(1): 61-68.
118. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24(6): 701-708.
119. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004; 43(1): 140-146.
120. Rao KV, Anderson WR, Kasiske BL, Dahl DC. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. The Am J Med 1993; 94(3): 241-250.
121. Orloff SL, Stempel CA, Wright TL, et al. Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clin Transplant 1995; 9(2): 119-124.
122. Fritsche C, Brandes JC, Delaney SR, et al. Hepatitis C is a poor prognostic indicator in black kidney transplant recipients. Transplantation 1993; 55(6): 1283-1287.
123. Ynares C, Johnson HK, Kerlin T, Crowe D, MacDonell R, Richie R. Impact of pretransplant hepatitis C antibody status upon long-term patient and renal allograft survival - a 5- and 10-year follow-up. Transplantation Proc 1993; 25(1 Pt 2): 1466-1468.
124. Mosconi G, Scolari MP, Morelli C, et al. Renal transplantation and HCV hepatitis: a longitudinal study. Transplantation Proc 2001; 33(1-2): 1185.
125. Sabet S, Hakemi M, Nadja. I, Ganji MR, Argani H, Broumand B. Impact of hepatitis C virus infection on short-term outcome in renal transplantation: a single-center study. Transplantation Proc 2003; 35(7): 2699-2700.
126. Pol S, Legendre C, Saltiel C, et al. Hepatitis C virus in kidney recipients: Epidemiology and impact on renal transplantation. J Hepatol 1992; 15(1-2): 202-206.
127. Goffin E, Pirson Y, Cornu C, Geubel A, Squifflet JP, van Ypersele de Strihou C. Outcome of HCV infection after renal transplantation. Kidney Int 1994; 45(2): 551-555.
128. Goffin E, Pirson Y, van Ypersele de Strihou C. Implications of chronic hepatitis B or hepatitis C infection for renal transplant candidates. Nephrol Dial Transplant 1995; 10(suppl 6): 88-92.
129. Cruzado JM, Carrera M, Torras J, Grinyo JM. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1(2): 171-178.
130. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 2001; 72(2): 241-244.
131. Morales JM, Campistol JM, Dominguez-Gil B. Hepatitis C virus infection and kidney transplantation. Semin Nephrol 2002; 22(4): 365-374.
132. Gentil MA, Rocha JL, Rodriguez-Algarra G, et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14(10): 2455-2460.
133. Aroldi A, Lampertico P, Elli A, et al. Long-term evolution of anti-HCV-positive renal transplant recipients. Transplantation Proc 1998; 30(5): 2076-2078.
134. Fabrizi F, Bunnapradist S, Lunghi G, Martin P. Transplantation of kidneys from HCV-positive donors: a safe strategy? J Nephrol 2003; 16(5): 617-625.
135. Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007; 83(7): 853-857.
136. Batty DS, Jr., Swanson SJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001; 1(2): 179-184.
137. Hestin D, Guillemin F, Castin N, Le Faou A, Champigneulles J, Kessler M. Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation 1998; 65(5): 741-744.
138. Pol S, Garrigue V, Legendre C. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 335(7): 522; author reply 3.
139. Weir MR, Kirkman RL, Strom TB, Tilney NL. Liver disease in recipients of long-functioning renal allografts. Kidney Int 1985; 28(5): 839-844.
140. Fishman JA, Rubin RH, Koziel MJ, Periera BJ. Hepatitis C virus and organ transplantation. Transplantation 1996; 62(2): 147-154.
141. Younossi ZM, Braun WE, Protiva DA, Gifford RW, Jr., Straffon RA. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999; 67(2): 272-275.
142. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005; 5(10): 2433-2440.
143. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29(4): 608-614.
144. Rostaing L, Rumeau JL, Cisterne JM, Izopet J, Chabannier MH, Durand D. Liver histology in renal transplant patients after more than 10 years of hepatitis C virus infection. Transplantation Proc 1996; 28(5): 2836-2837.
145. Rao KV, Ma J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 1996; 62(12): 1765-1769.
146. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54(2): 650-671.
147. Roth D, Cirocco R, Zucker K, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995; 59(12): 1676-1682.
148. Hammoud H, Haem J, Laurent B, et al. Glomerular disease during HCV infection in renal transplantation. Nephrol Dial Transplant 1996; 11(suppl 4): 54-55.
149. Baid S, Pascual M, Williams WW, Jr., et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10(1): 146-153.
150. Morales JM, Campistol JM, Andres A, Rodicio JL. Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 1997; 6(6): 511-515.
151. Stehman-Breen C, Alpers CE, Fleet WP, Johnson RJ. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron 1999; 81(1): 37-40.
152. Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000; 70(2): 255-261.
153. Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63(11): 1634-1639.
154. Gallay BJ, Alpers CE, Davis CL, Schultz MF, Johnson RJ. Glomerulonephritis in renal allografts associated with hepatitis C infection: a possible relationship with transplant glomerulopathy in two cases. Am J Kidney Dis 1995; 26(4): 662-627.
155. Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1(8384): 989-990.
156. Kovarik J, Mayer G, Pohanka E, et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients: cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 1988; 45(2): 402-405.
157. Fernández I, Meneu JC, Colina F, et al. Clinical and histological ef.cacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12(12): 1805-1812.
158. Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008; 18(2): 97-115.
159. Casanovas-Taltavull T, Baliellas C, Llobet M, et al. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc 2007; 39(7): 2125-2127.
160. Schmitz V, Kiessling A, Bahra M, et al. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant. 2007; 12(3): 22-27.